智通财经APP讯，心泰医疗(02291)公布2024年业绩，收入约4.72亿元，同比增长44.4%。毛利约4.24亿元，同比增长46.7%。归属于母公司股东的净利润约2.456亿元，同比增长62.2%。末期股息每股0.62元(含税)。
于本公告日期，该集团共拥有11款已完成商业化的先天性心脏病封堵器产品，其中，第三代MemoCarna®氧化膜单铆封堵器系列产品于2020年获批上市后，迅速成为先天性心脏病封堵器产品线的中坚力量。继第四代MemoSorb®全降解封堵器于2022年获批上市后，公司欣然看到，第四代MemoSorb®生物可降解房间隔缺损封堵器产品亦于2024年8月14日取得国家药监局授出的医疗器械注册证。这两款产品已经迅速实现商业化，并成为集团在先天性心脏病领域的旗舰产品。依靠厚积薄发的技术积淀，通过技术升级、产品迭代和独创性技术，使得我们在先天性心脏病介入治疗领域保持领先态势，先天性心脏病医疗器械是公司的重要基本面，在此基础上，公司得以通过外延式发展，进入各项业务快速增长的全新阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.